MX2015002947A - Terapia de combinacion de un anticuerpo ant-cd20 tipo ii con un inhibidor blc-2 selectivo. - Google Patents
Terapia de combinacion de un anticuerpo ant-cd20 tipo ii con un inhibidor blc-2 selectivo.Info
- Publication number
- MX2015002947A MX2015002947A MX2015002947A MX2015002947A MX2015002947A MX 2015002947 A MX2015002947 A MX 2015002947A MX 2015002947 A MX2015002947 A MX 2015002947A MX 2015002947 A MX2015002947 A MX 2015002947A MX 2015002947 A MX2015002947 A MX 2015002947A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- inhibitor
- type
- combination therapy
- selective bcl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Abstract
La presente invención se dirige a una terapia de combinación que involucra un anticuerpo anti-CD20 tipo II y un inhibidor Bcl-2 selectivo para el tratamiento de un paciente que padece de cáncer, particularmente, un cáncer que expresa CD20.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261698379P | 2012-09-07 | 2012-09-07 | |
PCT/US2013/058557 WO2014039855A1 (en) | 2012-09-07 | 2013-09-06 | Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015002947A true MX2015002947A (es) | 2015-09-23 |
Family
ID=49253396
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015002947A MX2015002947A (es) | 2012-09-07 | 2013-09-06 | Terapia de combinacion de un anticuerpo ant-cd20 tipo ii con un inhibidor blc-2 selectivo. |
Country Status (11)
Country | Link |
---|---|
US (12) | US9539251B2 (es) |
EP (2) | EP3919079A1 (es) |
JP (4) | JP6408993B2 (es) |
KR (2) | KR102158467B1 (es) |
CN (3) | CN111437386A (es) |
CA (1) | CA2884307A1 (es) |
HK (1) | HK1212240A1 (es) |
MX (1) | MX2015002947A (es) |
NZ (1) | NZ630166A (es) |
RU (1) | RU2648476C2 (es) |
WO (1) | WO2014039855A1 (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9296820B2 (en) | 2003-11-05 | 2016-03-29 | Roche Glycart Ag | Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function |
KR101486615B1 (ko) | 2007-07-16 | 2015-01-28 | 제넨테크, 인크. | 항-cd79b 항체 및 면역접합체 및 사용 방법 |
ES2528922T3 (es) | 2007-07-16 | 2015-02-13 | Genentech, Inc. | Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso |
TWI607019B (zh) | 2008-01-31 | 2017-12-01 | 建南德克公司 | 抗-cd79b抗體及免疫共軛物及使用方法 |
US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
MX342405B (es) | 2010-06-03 | 2016-09-28 | Pharmacyclics Inc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
CN103987711B (zh) | 2011-10-14 | 2016-08-24 | 艾伯维公司 | 作为用于治疗癌症和免疫性和自身免疫性疾病的凋亡诱导剂的8-氨基甲酰基-2-(2,3-二取代吡啶-6-基)-1,2,3,4-四氢异喹啉衍生物 |
AU2013293087B2 (en) | 2012-07-24 | 2017-08-31 | Pharmacyclics Llc | Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK) |
CN111437386A (zh) | 2012-09-07 | 2020-07-24 | 吉宁特有限公司 | II型抗CD20抗体与选择性Bcl-2抑制剂的组合治疗 |
CN105899535A (zh) * | 2013-12-17 | 2016-08-24 | 豪夫迈·罗氏有限公司 | 用pd-1轴结合拮抗剂和抗cd20抗体治疗癌症的方法 |
HRP20211813T1 (hr) * | 2014-08-11 | 2022-03-04 | Acerta Pharma B.V. | Terapeutske kombinacije inhibitora btk i inhibitora bcl-2 |
US20160082120A1 (en) * | 2014-09-23 | 2016-03-24 | Genentech, Inc. | METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES |
TW201639573A (zh) * | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
JP6971153B2 (ja) * | 2015-06-23 | 2021-11-24 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | 多重特異的nkエンゲイジャータンパク質 |
PE20180602A1 (es) | 2015-06-24 | 2018-04-09 | Hoffmann La Roche | Anticuerpos anti-receptor de transferrina con afinidad disenada |
CN108473573A (zh) * | 2015-06-29 | 2018-08-31 | 豪夫迈·罗氏有限公司 | Ii型抗cd20抗体用于器官移植中 |
CN113607945A (zh) * | 2015-07-07 | 2021-11-05 | 豪夫迈·罗氏有限公司 | 抗HER2抗体-药物缀合物和Bcl-2抑制剂的组合疗法 |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
CN114014936A (zh) | 2015-10-02 | 2022-02-08 | 豪夫迈·罗氏有限公司 | 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法 |
EP3370775B1 (en) | 2015-11-03 | 2023-04-19 | Genentech, Inc. | Combination of bcl-2 inhibitor and mek inhibitor for the treatment of cancer |
CN107384932B (zh) | 2016-08-31 | 2020-10-20 | 北京天广实生物技术股份有限公司 | 抗人cd20人源化单克隆抗体mil62、其制备方法及用途 |
WO2018106945A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
EP4108183A1 (en) | 2017-03-30 | 2022-12-28 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
EP3672591B1 (en) * | 2018-07-31 | 2024-02-14 | Ascentage Pharma (Suzhou) Co., Ltd. | Synergistic antitumor effect of bcl-2 inhibitor combined with rituximab and/or bendamustine or bcl-2 inhibitor combined with chop |
AU2019314819A1 (en) | 2018-07-31 | 2020-10-22 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of Bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
US20210363245A1 (en) | 2018-09-17 | 2021-11-25 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Bicistronic chimeric antigen receptors targeting cd19 and cd20 and their uses |
CN113677346A (zh) | 2018-11-01 | 2021-11-19 | 希洛斯医药品股份有限公司 | 周期蛋白依赖性激酶7(cdk7)的抑制剂 |
US20230023414A1 (en) | 2018-11-19 | 2023-01-26 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
BR112022007179A2 (pt) | 2019-10-21 | 2022-08-23 | Novartis Ag | Inibidores de tim-3 e usos dos mesmos |
TW202128166A (zh) | 2019-10-21 | 2021-08-01 | 瑞士商諾華公司 | 組合療法 |
WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
AU2021378316A1 (en) | 2020-11-13 | 2023-06-01 | Novartis Ag | Combination therapies with chimeric antigen receptor (car)-expressing cells |
EP4314082A1 (en) | 2021-03-24 | 2024-02-07 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Bicistronic chimeric antigen receptors designed to reduce retroviral recombination and uses thereof |
EP4319800A1 (en) | 2021-04-07 | 2024-02-14 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for the treatment of cancer |
CN117241802A (zh) * | 2021-04-21 | 2023-12-15 | 新基公司 | 使用2-(2,6-二氧代哌啶-3-基)-4-((2-氟-4-((3-吗啉代氮杂环丁烷-1-基)甲基)苄基)氨基)异吲哚啉-1,3-二酮治疗非霍奇金淋巴瘤的方法 |
WO2024032410A1 (zh) * | 2022-08-09 | 2024-02-15 | 成都百裕制药股份有限公司 | 哌嗪类化合物和pd-1抑制剂或pd-l1抑制剂的组合物以及其***的用途 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
SK17282000A3 (sk) | 1998-05-15 | 2002-04-04 | Imclone Systems Incorporated | Nerádioaktívne označený inhibítor proteínového tyrozínkynázového receptora |
KR20100018071A (ko) | 2001-08-03 | 2010-02-16 | 글리카트 바이오테크놀로지 아게 | 항체 의존적 세포 독성이 증가된 항체 글리코실화 변이체 |
CA2481657A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
PL216630B1 (pl) | 2002-10-17 | 2014-04-30 | Genmab As | Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie |
US9296820B2 (en) * | 2003-11-05 | 2016-03-29 | Roche Glycart Ag | Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function |
US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
CA2662320C (en) | 2006-09-05 | 2014-07-22 | Abbott Laboratories | Bcl inhibitors treating platelet excess |
US20090098118A1 (en) | 2007-10-15 | 2009-04-16 | Thomas Friess | Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent |
US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
SG10201704742YA (en) | 2009-05-26 | 2017-07-28 | Abbvie Ireland Unlimited Co | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
EP2533810B1 (en) * | 2010-02-10 | 2016-10-12 | ImmunoGen, Inc. | Cd20 antibodies and uses thereof |
TWI520960B (zh) * | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
MX349533B (es) | 2010-10-29 | 2017-08-02 | Abbvie Inc | Dispersiones solidas que contienen un agente inductor de apoptosis. |
JP5876067B2 (ja) | 2010-11-23 | 2016-03-02 | アッヴィ・バハマズ・リミテッド | 選択的bcl−2阻害薬を用いた処置方法 |
CN107266435A (zh) | 2010-11-23 | 2017-10-20 | Abbvie 公司 | 细胞凋亡诱导剂的盐和晶形 |
CN111437386A (zh) | 2012-09-07 | 2020-07-24 | 吉宁特有限公司 | II型抗CD20抗体与选择性Bcl-2抑制剂的组合治疗 |
AR095265A1 (es) | 2013-03-13 | 2015-09-30 | Abbvie Inc | Procesos para la preparación de un agente inductor de la apoptosis |
AU2016267564B2 (en) | 2015-05-26 | 2022-09-01 | F. Hoffmann-La Roche Ag | Combination therapy of an anti CD20 antibody with a Bcl-2 inhibitor and a MDM2 inhibitor |
EP3370775B1 (en) * | 2015-11-03 | 2023-04-19 | Genentech, Inc. | Combination of bcl-2 inhibitor and mek inhibitor for the treatment of cancer |
-
2013
- 2013-09-06 CN CN202010088179.6A patent/CN111437386A/zh active Pending
- 2013-09-06 KR KR1020157008862A patent/KR102158467B1/ko active IP Right Grant
- 2013-09-06 CA CA2884307A patent/CA2884307A1/en active Pending
- 2013-09-06 KR KR1020207026653A patent/KR20200110711A/ko active Application Filing
- 2013-09-06 NZ NZ630166A patent/NZ630166A/en unknown
- 2013-09-06 EP EP21173041.1A patent/EP3919079A1/en active Pending
- 2013-09-06 RU RU2015112576A patent/RU2648476C2/ru active
- 2013-09-06 WO PCT/US2013/058557 patent/WO2014039855A1/en active Application Filing
- 2013-09-06 CN CN201380057990.6A patent/CN104768581A/zh active Pending
- 2013-09-06 MX MX2015002947A patent/MX2015002947A/es active IP Right Grant
- 2013-09-06 CN CN202010088180.9A patent/CN111481552A/zh active Pending
- 2013-09-06 JP JP2015531246A patent/JP6408993B2/ja active Active
- 2013-09-06 EP EP13767170.7A patent/EP2892557A1/en not_active Withdrawn
- 2013-09-06 US US14/020,761 patent/US9539251B2/en active Active
-
2016
- 2016-01-13 HK HK16100331.0A patent/HK1212240A1/xx unknown
- 2016-11-30 US US15/365,595 patent/US11413282B2/en active Active
-
2018
- 2018-07-03 JP JP2018126675A patent/JP6637119B2/ja active Active
-
2019
- 2019-12-18 JP JP2019227891A patent/JP2020063279A/ja active Pending
-
2020
- 2020-03-23 US US16/827,650 patent/US10993942B2/en active Active
-
2021
- 2021-02-26 US US17/187,468 patent/US11110087B2/en active Active
- 2021-03-05 US US17/193,795 patent/US20220008413A1/en not_active Abandoned
- 2021-08-05 US US17/395,366 patent/US20220211696A1/en not_active Abandoned
-
2022
- 2022-03-30 US US17/709,324 patent/US20220265642A1/en not_active Abandoned
- 2022-04-08 JP JP2022064357A patent/JP2022091996A/ja active Pending
- 2022-06-07 US US17/834,709 patent/US11590128B2/en active Active
-
2023
- 2023-01-20 US US18/157,680 patent/US20230226045A1/en not_active Abandoned
- 2023-03-28 US US18/191,810 patent/US20230255959A1/en not_active Abandoned
- 2023-09-07 US US18/463,252 patent/US20240000776A1/en active Pending
- 2023-11-10 US US18/506,606 patent/US20240108616A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015002947A (es) | Terapia de combinacion de un anticuerpo ant-cd20 tipo ii con un inhibidor blc-2 selectivo. | |
IL276434A (en) | Combined treatment involving antibodies against claudin 18.2 for the treatment of cancer | |
IL279330A (en) | Combined treatment including antibodies against Claudin 18.2 for the treatment of cancer | |
PH12016500839A1 (en) | Combination theraphy of an anti cd20 antibody with a btk inhibitor | |
MX2013006392A (es) | Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1. | |
MX2014005458A (es) | Inhibidor doble de met y del factor de crecimiento endotelial vascular (vegf) para el tratamiento del cáncer. | |
MX2016002645A (es) | Tratamiento combinado para tratar el glioblastoma. | |
MX2013006739A (es) | Terapia combinada de anticuerpo cd20 afucosilado con inhibidor de mdm2. | |
MX360189B (es) | Terapia de combinacion para el tratamiento de glioblastoma. | |
PH12014501543A1 (en) | Combination therapy for the treatment of ovarian cancer | |
MX347463B (es) | Terapia de combinación de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf. | |
PL2852408T3 (pl) | Terapia skojarzona obejmująca przeciwciała przeciwko Klaudynie 18.2 do leczenia nowotworu | |
WO2012106473A3 (en) | Dosing for treatment with anti-egfl7 antibodies | |
MX2018000135A (es) | Terapia combinada con un conjugado de farmaco y anticuerpo anti receptor 2 de factor de crecimiento epidermico humano (her2) y un inhibidor de linfoma de celulas b2 (bcl-2). |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |